Michael Shuler,
Samuel B. Eckert Professor of Engineering,
Cornell University, President Hesperos, Inc.
Michael L. Shuler is the Eckert Professor of Engineering, Emeritus in the Meing Department of Biomedical Engineering and in the Smith School of Chemical and Biomolecular Engineering at Cornell University, and was director of Cornell’s Nanobiotechnology Center. Shuler has degrees in chemical engineering (BS, Notre Dame, 1969 and Ph.D., Minnesota, 1973) and has been a faculty member at Cornell University since 1974. Shuler’s research includes development of “Body-on-a-Chip” for testing pharmaceuticals for toxicity and efficacy, creation of production systems for useful compounds, such as paclitaxel from plant cell cultures, and construction of whole cell models relating genome to physiology. Shuler is CEO and President of Hesperos, a company founded to implement the “Body-on-a-Chip” system. Shuler and F. Kangi have authored a popular textbook, “Bioprocess Engineering; Basic Concepts” now in its third edition. He has an honorary doctorate from the University of Notre Dame. Shuler has been elected to the National Academy of Engineering and the American Academy of Arts and Science and is a fellow of numerous professional societies.
Human In Vitro Models to Improve Preclinical Testing of Drugs
Tuesday, 15 October 2019 at 09:00
Add to Calendar ▼2019-10-15 09:00:002019-10-15 10:00:00Europe/LondonHuman In Vitro Models to Improve Preclinical Testing of DrugsOrgan-on-a-Chip World Congress 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Human microphysiological or “Body-on-a-Chip” systems are powerful tools to assess the potential efficacy and toxicity of drugs in pre-clinical studies. Having a human based, multiorgan system, that emulates key aspects of human physiology can provide important insights to complement animal studies and in vitro studies using human cells from a single organ in the decision about which drugs to move into clinical trials1. Our human surrogates are constructed using a low cost, robust “pumpless” platform. We use this platform in conjunction with “functional” measurements of electrical and mechanical activity of tissue constructs (in collaboration with J. Hickman, University of Central Florida). Also by combining PBPK-PD models2 with these devices we can enhance our predictive power for anticipating human responses. Using a system with four or more organs we can predict the exchange of metabolites between organ compartments in response to various drugs and dose levels. We have constructed models incorporating barrier tissues such as GI tract, blood brain barrier, and skin with internal organs such as liver, cardiac, and neuromuscular junctions. With these systems, we can predict both efficacy and toxicity of drugs in humans from preclinical studies3. Further, we can use these systems to investigate temporal concentration relationships of drugs during preclinical development4. We believe that these “Body-on-a-Chip” systems have great potential to increase the efficiency of conversion of drug candidates into successful projects.
Add to Calendar ▼2019-10-14 00:00:002019-10-15 00:00:00Europe/LondonOrgan-on-a-Chip World Congress 2019Organ-on-a-Chip World Congress 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2019-10-15 09:00:002019-10-15 10:00:00Europe/LondonHuman In Vitro Models to Improve Preclinical Testing of DrugsOrgan-on-a-Chip World Congress 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
.jpg)